📇 Rhumatologue · TOURS CEDEX 9 · (37) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
17 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
131.9 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
13
13 articles ont été cités au moins 13fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
1 007
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
29
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
13
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Centre Hospitalier Universitaire de Tours
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Prognostic factors in interstitial lung disease-associated pulmonary hypertension: data from the HYPID cohort and the French Pulmonary Hypertension Registry
2026ArticleEuropean Respiratory Journal
Pulmonary hypertension in patients with Noonan syndrome
2025ArticleEuropean Respiratory Journal
Seven cases of hereditary haemorrhagic telangiectasia-like hepatic vascular abnormalities associated with EPHB4 pathogenic variants
2023ArticleJournal of Medical Genetics
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study
2022ArticleThe Lancet Respiratory Medicine
COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study
2022ArticleAmerican Journal of Respiratory and Critical Care Medicine
Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT
2022ArticleOrphanet Journal of Rare Diseases
Association Between Initial Treatment Strategy and Long-term Survival in Pulmonary Arterial Hypertension
2021ArticleAmerican Journal of Respiratory and Critical Care Medicine
Corrigendum to: “Portopulmonary hypertension in the current era of pulmonary hypertension management” [J Hepatol (2020);73:130–139]
2020ArticleJournal of Hepatology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHRU BRETONNEAU - TOURS
2 BD TONNELLE, 37044 TOURS CEDEX 9
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
The Lancet. Respiratory medicine · 2022
American journal of respiratory and critical care medicine · 2021
Abstract Rationale The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives To evaluate the long-term survival of patients with PAH categorized according to the initial treatment strategy. Methods A retrospective analysis of incident patients with idiopathic, heritable, or anorexigen-induced PAH enrolled in the French Pulmonary Hypertension Registry (January 2006 to December 2018) was conducted. Survival was assessed according to the initial strategy: monotherapy, dual therapy, or triple-combination therapy (two oral medications and a parenteral prostacyclin). Measurements and Main Results Among 1,611 enrolled patients, 984 were initiated on monotherapy, 551 were initiated on dual therapy, and 76 were initiated on triple therapy. The triple-combination group was younger and had fewer comorbidities but had a higher mortality risk. The survival rate was higher with the use of triple therapy (91% at 5 yr) as compared with dual therapy or monotherapy (both 61% at 5 yr) (P < 0.001). Propensity score matching of age, sex, and pulmonary vascular resistance also showed significant differences between triple therapy and dual therapy (10-yr survival, 85% vs. 65%). In high-risk patients (n = 243), the survival rate was higher with triple therapy than with monotherapy or dual therapy, whereas there was no difference between monotherapy and double therapy. In intermediate-risk patients (n = 1,134), survival improved with an increasing number of therapies. In multivariable Cox regression, triple therapy was independently associated with a lower risk of death (hazard ratio, 0.29; 95% confidence interval, 0.11–0.80; P = 0.017). Among the 148 patients initiated on a parenteral prostacyclin, those on triple therapy had a higher survival rate than those on monotherapy or dual therapy. Conclusions Initial triple-combination therapy that includes parenteral prostacyclin seems to be associated with a higher survival rate in PAH, particularly in the youngest high-risk patients.
Journal of hepatology · 2020
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Chest · 2026 · Journal Article
Lacoste-Palasset T, Baron A, Ebstein N, Beurnier A, et al.
The European respiratory journal · 2025 · Journal Article
Grynblat J, Farges M, Magro P, Savale L, et al.
Journal of medical genetics · 2023 · Journal Article
Guilhem A, Dupuis-Girod S, Espitia O, Rivière S, et al.
American journal of respiratory and critical care medicine · 2021 · Evaluation Study
Boucly A, Savale L, Jaïs X, Bauer F, et al.
Journal of hepatology · 2020 · Published Erratum
Savale L, Guimas M, Ebstein N, Fertin M, et al.
American journal of respiratory and critical care medicine · 2020 · Journal Article
Jutant EM, Jaïs X, Girerd B, Savale L, et al.
Journal of hepatology · 2020 · Journal Article
Savale L, Guimas M, Ebstein N, Fertin M, et al.
Transplantation · 2018 · Journal Article
Reymond M, Barbier L, Salame E, Besh C, et al.
The European respiratory journal · 2017 · Journal Article
Weatherald J, Chaumais MC, Savale L, Jaïs X, et al.
The European respiratory journal · 2016 · Case Reports
Riou M, Seferian A, Savale L, Chaumais MC, et al.
Annals of the rheumatic diseases · 2016 · Journal Article
Sanges S, Launay D, Rhee RL, Sitbon O, et al.
International journal of cardiology · 2011 · Comparative Study
Laurent V, Pellieux S, Corcia P, Magro P, et al.
Journal of clinical ultrasound : JCU · 2008 · Journal Article
Tranquart F, Palanchon P, Cladé O, Bleuzen A, et al.
Intensive care medicine · 2005 · Case Reports
Ehrmann S, Bastides F, Gissot V, Mercier E, et al.
The European respiratory journal · 2026 · Journal Article
Diesler R, Turquier S, Reynaud-Gaubert M, Lestelle F, et al.
The Lancet. Respiratory medicine · 2022 · Clinical Trial, Phase III
Jaïs X, Brenot P, Bouvaist H, Jevnikar M, et al.
Orphanet journal of rare diseases · 2022 · Journal Article
Le TTT, Martinent G, Dupuis-Girod S, Parrot A, et al.
Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT
Abstract Background Hereditary hemorrhagic telangiectasia (HHT) disease is a rare genetic disorder with symptoms and complications that can significantly affect patients’ daily lives. To date, no scale has been validated
Additional file 2 of Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT
Additional file 2. Standardized Factor Loadings (λ) and Uniqueness (δ) for Confirmatory Factor Analysis (CFA), and Exploratory Structural Equation Modeling (ESEM) of the 29-item version of the QoL-HHT questionnaire.
Additional file 2 of Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT
Additional file 2. Standardized Factor Loadings (λ) and Uniqueness (δ) for Confirmatory Factor Analysis (CFA), and Exploratory Structural Equation Modeling (ESEM) of the 29-item version of the QoL-HHT questionnaire.
Additional file 3 of Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT
Additional file 3. Standardized factor loadings (λ) and Uniqueness (δ) for the bi-factor model of the 24- item version of the QoL-HHT questionnaire.
Additional file 1 of Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT
Additional file 1. Factor loading of the AFEs of the 78-item version of the preliminary QOL-HHT questionnaire.
Additional file 1 of Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT
Additional file 1. Factor loading of the AFEs of the 78-item version of the preliminary QOL-HHT questionnaire.
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).